|
|
|
|
|||||
|
|
|
Exact Sciences Corporation EXAS reported a net loss of 21 cents in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 37 cents. The reported figure compares with a loss of 50 cents in the same quarter last year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Consolidated revenues totaled $706.8 million, up 10.9% on a reported basis and 11% on a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 2.5%.
Following the announcement, EXAS shares increased 8.1% in after-hours trading yesterday.
Screening revenues, including laboratory service revenues from Cologuard tests and PreventionGenetics, increased 14% year over year to $540 million due to the ongoing Cologuard momentum.
Exact Sciences Corporation price-consensus-eps-surprise-chart | Exact Sciences Corporation Quote
Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $167 million, an increase of 2% from the year-ago quarter’s figure. This upside was propelled by the continued adoption of Oncotype DX internationally.
Exact Sciences’ gross profit rose 12.2% year over year to $500.5 million despite a 7.9% rise in the cost of revenues (excluding the amortization of acquired intangibles). The gross margin expanded 81 basis points (bps) to 70.8%.
Research and development expenses fell 5% year over year to $105.3 million. Sales and marketing expenses surged 21.4% to $264.3 million. General and administrative expenses edged up 0.5% year over year to $221 million.
Overall, the adjusted operating loss totaled $89.8 million compared with the year-ago operating loss of $102 million.
Exact Sciences exited the first quarter with cash and cash equivalents and marketable securities of $786 million compared with $1.04 billion at the end of the fourth quarter of 2024.
For full-year 2025, the company now anticipates total revenues in the range of $3.070-$3.120 billion (previously $3.025-$3.085 billion). The Zacks Consensus Estimate is pegged at $3.05 billion.
Among these, Screening revenues are expected in the range of $2.390-$2.425 billion (previously $2.350-$2.390 billion). Precision Oncology revenues are expected between $680 and $695 million (earlier $675-$695 million).
The adjusted EBITDA forecast is updated to the $425-$455 million band from the earlier range of $410-$440 million.
Exact Sciences exited the first quarter of 2025 with a narrower-than-expected loss and revenue beat. The results also came in above the company’s expectations amid one of the challenging flu seasons in recent years. Cologuard’s broad-based growth was led by continued success in rescreens, care gap programs and growth in new ordering providers. Exact Sciences launched its next-generation colon cancer screening test, Cologuard Plus, with Medicare coverage and quality measure inclusion, further enhancing its screening capabilities.
Additionally, year-over-year gross margin expansion and a reduced adjusted operating loss are highly encouraging. The raised revenue and adjusted EBITDA guidance for the full year also bodes well.
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AngioDynamics ANGO, Integer Holdings Corporation ITGR and Boston Scientific BSX.
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, exceeding the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| May-02 |
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Two Top Buy Point
BSX
Investor's Business Daily
|
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-02 | |
| May-01 | |
| May-01 | |
| May-01 | |
| May-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite